ALDR - Alder BioPharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.31
+0.85 (+6.32%)
At close: 4:00PM EDT

14.31 0.00 (0.00%)
After hours: 4:41PM EDT

Stock chart is not supported by your current browser
Previous Close13.46
Open13.45
Bid13.69 x 4000
Ask14.47 x 800
Day's Range13.22 - 14.91
52 Week Range9.44 - 20.87
Volume2,015,296
Avg. Volume1,126,025
Market Cap1.19B
Beta (3Y Monthly)3.45
PE Ratio (TTM)N/A
EPS (TTM)-4.87
Earnings DateJul 27, 2017 - Jul 28, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.47
Trade prices are not sourced from all markets
  • Markit9 days ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    Alder Biopharmaceuticals Inc NASDAQ NMS:ALDRView full report here! Summary * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NegativeShort interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 8. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ALDR had net inflows of $739 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire16 days ago

    Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference

    BOTHELL, Wash, March 05, 2019 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • GlobeNewswire17 days ago

    Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the closing of its previously announced underwritten public offering of 13,000,000 shares of common stock, including 1,695,652 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $11.50 per share. Concurrent with the public offering, Alder sold, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), 1,739,130 shares of common stock to certain institutional and other accredited investors affiliated with or managed by Redmile Group, LLC at a sale price equal to $11.50 per share.

  • GlobeNewswire20 days ago

    Recent Analysis Shows McDermott International, Nu Skin Enterprises, Marcus, Keysight Technologies, Alder BioPharmaceuticals, and LendingTree Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of ALDR earnings conference call or presentation 25-Feb-19 10:00pm GMT

    Q4 2018 Alder Biopharmaceuticals Inc Earnings Call

  • GlobeNewswire22 days ago

    Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the pricing of an underwritten public offering of 11,304,348 shares of its common stock at a price to the public of $11.50 per share. In addition, Alder has granted the underwriters a 30-day option to purchase up to 1,695,652 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Concurrent with the public offering, Alder intends to sell, subject to the consummation of the public offering and other customary conditions, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), 1,739,130 shares of common stock to certain institutional and other accredited investors affiliated with or managed by Redmile Group, LLC at a sale price equal to $11.50 per share.

  • GlobeNewswire23 days ago

    Alder BioPharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today that it intends to offer and sell, subject to market and other conditions, up to $105 million of shares of its common stock in an underwritten public offering. In connection with this offering, Alder expects to grant the underwriters a 30-day option to purchase up to $15.75 million of additional shares of common stock. Concurrent with the public offering, Alder intends to sell, subject to the consummation of the public offering and other customary conditions, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), up to $20 million of shares of common stock to certain institutional and other accredited investors affiliated with or managed by Redmile Group, LLC at a sale price equal to the price to the public in the public offering.

  • Alder BioPharmaceuticals Inc (ALDR) Q4 2018 Earnings Conference Call Transcript
    Motley Fool24 days ago

    Alder BioPharmaceuticals Inc (ALDR) Q4 2018 Earnings Conference Call Transcript

    ALDR earnings call for the period ending December 31, 2018.

  • GlobeNewswire24 days ago

    Alder BioPharmaceuticals® Reports Fourth Quarter and Full Year 2018 Financial and Operating Results

    - Completes eptinezumab’s Biologics License Application (BLA) submission - - Remains on track for eptinezumab’s commercial launch in Q1-2020 - - Strengthens leadership.

  • ACCESSWIRE24 days ago

    Alder Biopharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, ...

  • GlobeNewswire27 days ago

    Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 60,000 shares of Alder’s common stock to a new employee under Alder’s 2018 Inducement Award Plan, effective February 18, 2019. The stock option will vest with respect to 25% of the shares underlying the option one year after the employee’s employment start date and the remaining 75% of the shares underlying the option will vest in equal monthly installments over the 36 month period following the one year anniversary of the employee’s employment start date, subject to the employee’s continued service to Alder through each relevant vesting date.  The option has a ten year term and an exercise price of $13.98 per share, which is equal to the closing price of Alder’s common stock on February 18, 2019.

  • GlobeNewswire27 days ago

    Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for eptinezumab. Eptinezumab is an investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide (CGRP) and is Alder’s lead commercial candidate. If the BLA submission is accepted and the FDA grants approval of eptinezumab, Alder will be on track for a Q1 2020 commercial launch.

  • GlobeNewswire28 days ago

    Alder BioPharmaceuticals® to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    BOTHELL, Wash., Feb. 21, 2019 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • GlobeNewswirelast month

    Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial and Operating Results

    BOTHELL, Wash., Feb. 19, 2019 -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
    Investor's Business Dailylast month

    Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst

    An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.

  • GlobeNewswirelast month

    Consolidated Research: 2019 Summary Expectations for Varonis, Dolby Laboratories, Alder BioPharmaceuticals, Retail Properties of America, Cerus, and Motorcar Parts of America — Fundamental Analysis, Key Performance Indications

    NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates
    Zackslast month

    Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates

    Molina Healthcare's (MOH) fourth-quarter earnings trump estimates on the back of lower costs and higher premium revenues.

  • Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y
    Zackslast month

    Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y

    Ensign Group's (ENSG) fourth-quarter earnings rise on the back of solid segmental growth.

  • MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y
    Zackslast month

    MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y

    Mednax's (MD) Q4 gains on revenue growth. However, the same is partly offset by rise in expenses.

  • Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?
    Zackslast month

    Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?

    Molina Healthcare (MOH) is expected to gain in Q4 on the back of membership strength and its streamlining initiative. However, the same might be partly offset by a dismal Marketplace business.

  • Alder BioPharmaceuticals (ALDR) Upgraded to Buy: What Does It Mean for the Stock?
    Zackslast month

    Alder BioPharmaceuticals (ALDR) Upgraded to Buy: What Does It Mean for the Stock?

    Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
    Zacks2 months ago

    MacroGenics Up on Lifting of Partial Hold on Cancer Candidate

    MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.